Pure Bioscience, Inc. (OTCMKTS:PURE) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 27,300 shares, a growth of 58.7% from the September 15th total of 17,200 shares. Based on an average daily volume of 106,400 shares, the short-interest ratio is presently 0.3 days.
Shares of OTCMKTS:PURE traded up $0.10 on Friday, hitting $1.51. The stock had a trading volume of 80,330 shares, compared to its average volume of 134,314. Pure Bioscience has a twelve month low of $0.20 and a twelve month high of $2.05. The firm’s 50 day moving average price is $1.54 and its 200-day moving average price is $1.29. The company has a market capitalization of $131.48 million, a price-to-earnings ratio of -75.50 and a beta of 0.06.
Pure Bioscience (OTCMKTS:PURE) last issued its earnings results on Thursday, October 8th. The company reported $0.02 EPS for the quarter. The company had revenue of $3.95 million for the quarter. Pure Bioscience had a negative net margin of 59.68% and a negative return on equity of 129.24%.
A hedge fund recently bought a new stake in Pure Bioscience stock. Kirr Marbach & Co. LLC IN bought a new stake in shares of Pure Bioscience, Inc. (OTCMKTS:PURE) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 13,830 shares of the company’s stock, valued at approximately $25,000. 0.02% of the stock is currently owned by hedge funds and other institutional investors.
About Pure Bioscience
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds.
Read More: How to calculate compound interest
Receive News & Ratings for Pure Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pure Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.